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Abstract
Background: Insulin-like Growth Factor 1 (IGF1) is a multifunctional regulator of somatic growth and development
throughout evolution. IGF1 signaling through IGF type 1 receptor (IGF1R) controls cell proliferation, survival and
differentiation in multiple cell types. IGF1 deficiency in mice disrupts lung morphogenesis, causing altered prenatal
pulmonary alveologenesis. Nevertheless, little is known about the cellular and molecular basis of IGF1 activity during lung
development.
Methods/Principal Findings: Prenatal Igf12/2 mutant mice with a C57Bl/6J genetic background displayed severe
disproportional lung hypoplasia, leading to lethal neonatal respiratory distress. Immuno-histological analysis of their lungs
showed a thickened mesenchyme, alterations in extracellular matrix deposition, thinner smooth muscles and dilated blood
vessels, which indicated immature and delayed distal pulmonary organogenesis. Transcriptomic analysis of Igf12/2 E18.5
lungs using RNA microarrays identified deregulated genes related to vascularization, morphogenesis and cellular growth,
and to MAP-kinase, Wnt and cell-adhesion pathways. Up-regulation of immunity-related genes was verified by an increase
in inflammatory markers. Increased expression of Nfib and reduced expression of Klf2, Egr1 and Ctgf regulatory proteins as
well as activation of ERK2 MAP-kinase were corroborated by Western blot. Among IGF-system genes only IGFBP2 revealed a
reduction in mRNA expression in mutant lungs. Immuno-staining patterns for IGF1R and IGF2, similar in both genotypes,
correlated to alterations found in specific cell compartments of Igf12/2 lungs. IGF1 addition to Igf12/2 embryonic lungs
cultured ex vivo increased airway septa remodeling and distal epithelium maturation, processes accompanied by up-
regulation of Nfib and Klf2 transcription factors and Cyr61 matricellular protein.
Conclusions/Significance: We demonstrated the functional tissue specific implication of IGF1 on fetal lung development in
mice. Results revealed novel target genes and gene networks mediators of IGF1 action on pulmonary cellular proliferation,
differentiation, adhesion and immunity, and on vascular and distal epithelium maturation during prenatal lung development.
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Introduction
Insulin-like Growth Factor 1 (IGF1) is a member of the insulin
family involved in the control of tissue development and
homeostasis by regulating multiple cell functions including
proliferation, differentiation, survival, adhesion and migration.
IGF1 acts primarily through its high affinity tyrosine kinase
receptor IGF1R. IGF1 and IGF1R, in combination with the
related ligand IGF2, six binding proteins with high affinity for
IGFs (IGFBP 1–6), modulators of IGFs activity, and a second non-
signaling receptor that reduces IGF2 signaling (IGF2R), constitute
the IGF signaling system. Expression of IGF system genes is tightly
regulated in a cell-type specific and spatiotemporal manner, and in
addition to their endocrine actions, IGF1 and IGF2 are also
frequently produced in autocrine and paracrine manners. Binding
of IGFs to IGF1R causes activation of various signaling pathways,
including mitogen-activated protein kinases (MAPK), PI3 kinase/
Akt and STATs, which regulate their multiple functions [1–3].
Experimental evidence demonstrates that IGFs play key roles in
prenatal lung growth and organogenesis. In humans, several
mutations in both IGF1 and IGF1R genes have been associated
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with intrauterine growth retardation [4,5]. One of these patients,
with a deletion that included the IGF1R gene, was reported to have
lung hypoplasia [6]. IGF1 expression is deregulated in stillborn
infants with respiratory and bronchopulmonary distress syn-
dromes, and with congenital diaphragmatic hernia, diseases
characterized by a severe degree of pulmonary hypoplasia and
immaturity [7–9]. Finally, blocking IGF1R signaling in cultured
human fetal lungs interfered with normal vascularization [10].
Parallel studies on genetically modified mice are contributing to
better understanding the role of IGFs in pulmonary development
and genetically support the fact that IGFs signaling contribute to
the control of prenatal mouse lung growth and differentiation.
Thus, mice carrying a homozygous null mutation of the Igf1 gene
(Igf12/2) are born 60% of the size of their littermates and show
atelectatic lungs that cause high postnatal mortality [11–13].
Accordingly, Igf1r2/2 mice are born 45% of the size of their
littermates and all of them die at birth due to immature collapsed
lungs and respiratory failure [11,13,14]. However, perinatal
Igf22/2 mice despite showing a growth deficiency similar to
Igf12/2, all survive at birth and only those born from Igf22/2
dams display a mild lung phenotype with slightly affected alveolar
sacs [13,15].
In mice, lung organogenesis prior to embryonic (E) day 16,
during the pseudoglandular stage, mainly consists of branching
morphogenesis with active proliferation of all cellular components.
During the canalicular stage (E16.5–E17.5) there is active
organization of the lung vascular bed, with numerous capillaries
scattered throughout the abundant mesenchyme, and the airway
epithelium cells change to columnar in proximal bronchioles and
to cuboidal in the incipient airway saccules alveolar sacs. After
E17.5, when the lung enters the saccular stage, cell proliferation
declines and differentiation predominates. Overall, the sacculation
process increases the efficiency of fluid absorption and prepares
the gas exchange mechanism required at birth, which occurs in
mice around E19, by means of significant morphogenetic changes
and massive cell differentiation. During this period, a high
proportion of distal lung epithelial cells flatten, thin out and
spread to form postmitotic type I alveolar cells, while a minority
remain cuboidal, acquire surfactants, and differentiate into type II
cells. The distal saccular septa become thinner due to a reduction
in mesenchymal cells, and the loose network of capillaries
coalesces with type I cells by fusion of their respective basement
membranes [16–19]. Despite advances made in understanding
prenatal mammalian lung morphogenesis, the molecular mecha-
nisms underlying this process remain poorly understood. IGF1 and
IGF1R are broadly expressed during rodent lung organogenesis,
with high levels of IGF1 preferentially present in mesenchymal
cells, and IGF1R mainly found in epithelial and endothelial cells
[20–22]. We have previously shown that IGF1 deficiency in the
neonatal mouse encompasses collapsed air spaces and altered
distal lung septa remodeling, characterized by changes in the
expression of markers for epithelial type I and type II, and
endothelial pulmonary cells [23,24]. In addition, IGF1 was found
to induce epithelium and vascular maturation in late stages of
mouse fetal distal lung development [25]. Nevertheless, the cellular
and molecular mechanisms by which IGF1 governs this process
remain to be completely elucidated.
In the present study, we examined the lungs of Igf12/2 E18.5
mouse embryos with an inbred genetic background to analyze
their prenatal lung phenotype at the cellular and molecular levels.
These lungs showed disproportional hypoplasia and retarded
development, characterized by a disorganized extracellular matrix
and dilated capillaries. A transcriptomic analysis using microarrays
identified differentially expressed genes in the Igf12/2 lungs
involved in diverse cellular functions and molecular pathways
reflecting immature and inflamed phenotypes. Functional valida-
tion of some of these genes using embryonic lung lobes cultured ex
vivo revealed that the transcription factors Nfib and Klf2 and the
CCN matricellular proteins Cyr61 and Ctgf mediate IGF1 actions
on pulmonary maturation. Thus, the mouse mutant model, in
addition and in combination with the approach using cultures of
explanted embryonic lungs, may prove valuable in unveiling
cellular and molecular mechanisms implicated in prenatal lung
maturation and elucidating the role of IGF1 in this process.
Results
Postnatal Mortality and Disproportional Embryonic Lung
Hypoplasia in Igf12/2 Mice Backcrossed to a C57Bl/6J
Genetic Background
Igf1+/2 mice containing the null Igf1 gene locus [11] were
backcrossed with the inbred C57Bl/6J strain, to avoid the highly
variable lung phenotype observed in the previous mixed genetic
background [23,24]. In this new colony, 100% of the homozygous
Igf12/2 mice died shortly after birth due to apparent respiratory
failure, contrasting to the 60% neonatal mortality observed in the
previous setting [24]. In addition, the E18.5 prenatal homozygous-
null embryos showed a 42% reduction in body weight
(1143.56139.8 mg in Igf1+/+ vs. 665.2682.3 mg in Igf12/2),
which was also higher than the previous 34% reduction reported
for embryos of mixed background [13,24]. Both results demon-
strate the critical effect of the mouse strain genetic background on
the phenotype of Igf1 mutants.
In Igf12/2 E18.5 embryos, the lung-to-body-weight ratio was
highly reduced when compared to Igf1+/+ controls, with a
significant reduction, 50% compared to their normal littermates
(Fig. 1A), demonstrating that although IGF1 functions as a general
growth factor for the entire organism during the embryonic period
[12,13], its role is even more crucial for proper prenatal lung
growth. In an attempt to explain the retarded growth of prenatal
Igf12/2 lungs, we analyzed their cell death and proliferation rates.
To compare cell death levels between genotypes, lung sections
were stained with DAPI to detect nuclear integrity, but no
differences were found. When we tested apoptotic levels using
TUNEL (TdT-mediated dUTP nick labeling) or cleaved caspase-3
immuno-staining, neither technique revealed significant differenc-
es between genotypes (data not shown). Interestingly, despite the
decline in lung size, proliferation rates in E18.5 Igf12/2 lungs were
higher, as shown by proliferation cell nuclear antigen (PCNA) (Fig.
S1A–B) and BrdU immuno-staining (data not shown). These
results in apoptosis and proliferation match the previously
reported in embryonic lungs of the outbred Igf1 mutants [23].
Afterwards, we analyzed the size and proliferation rates of lungs
during the early stages of lung development using an organ culture
approach. After 6 h of ex vivo culture, the flattened E12.5 Igf12/2
lung primordia showed a significant reduction in terminal lung
buds and surface as compared to normal explants (Fig. 1B–D), as
well as lower incorporation rates of bromodeoxyuridine (BrdU)
(Fig. 1E–F). The smaller size and reduced proliferation rates found
in E12.5 Igf12/2 explanted lungs suggests that the disproportional
growth retardation of prenatal E18.5 Igf12/2 lungs could be a
consequence of their diminished growth rates during early stages
of organogenesis.
IGF1 Role in Prenatal Lung Development
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Delayed distal differentiation and abnormalities in
extracellular matrix, smooth muscle and blood vessels in
the lung of Igf12/2 mice
Detailed histological analysis of E18.5 distal lung areas showed a
dense glandular appearance with reduced air spaces, poorly
defined saccular septa, presence of hyaline membrane-like content
filling the air spaces, and capillaries immersed in the septal
mesenchyme of Igf12/2 mice (Fig. S1C–D), which corresponds to
the results previously reported in outbred mutant mice [11,23].
Thus, the histology of Igf12/2 lungs better resembled an earlier
pseudoglandular staging rather than the expected saccular
Figure 1. Disproportionately smaller fetal lungs in Igf12/2mice and decreased proliferation during early pulmonary organogenesis.
(A) Graphical representation of lung-to-body weight ratio in normal (+/+) and Igf12/2 (2/2) E18.5 fetuses (shown as mean % 6 SEM). ***p,0.001
(Mann-Whitney U test). In parentheses, number of samples determined. Note that absence of IGF1 during embryonic development
disproportionately reduces lung growth. (B–D) Growth deficiency in E12.5 explanted lungs after 6 h of ex vivo culture. Microphotographs of lung
explants in (B) show a reduced number of terminal lung buds, represented in (C) (mean number 6 SEM), and smaller surface, represented in (D)
(mean surface 6 SEM), of the Igf12/2 explants. *p,0.05; ***p,0.001 (Mann-Whitney U test). In parentheses, number of samples determined. (E–F)
Cell proliferation in E12.5 explanted lungs cultured in defined medium for 48 h and pulse-chased with BrdU. Representative confocal images of
whole-mount lungs analyzed from independent experiments immuno-labeled for BrdU in red (yellow arrowheads) and counterstained in green with
Sytox, show more BrdU-labeled cells in Igf1+/+ (E), than do Igf12/2 explanted lungs (F) (n = 5 per genotype). as, airway space. Scale bar: 250 mm in B
and 30 mm in E–F.
doi:10.1371/journal.pone.0083028.g001
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morphology that is shown by the controls. Due to the loose
pulmonary histological appearance and considering the key roles
played by extracellular matrix (ECM) components during lung
development as well as the possible roles of IGF1 in pulmonary
ECM synthesis [26], we decided to evaluate whether ECM
components were altered in the embryonic Igf12/2 lungs.
Immuno-fluorescence analysis of E18.5 lungs and ex vivo cultured
E12.5 lung primordia revealed discontinuous and weaker laminin
staining in the Igf12/2 lungs (Fig. 2A–D). Although no differences
were found after quantification of total lung collagen contents
between genotypes (data not shown), the lung collagen-staining
pattern in terminal sacs septa was found to be more diffuse and
disorganized in the Igf1-null lungs (Fig. 2E–F). Since elastin
deposition was reported to be essential for alveolar septa formation
and normal alveologenesis [27], we next performed elastin staining
in lung sections. Elastic fiber staining in mesenchymal areas did
not reveal differences between genotypes (data not shown), but the
arterial walls showed a less intense staining and a looser
arrangement in thinner layers of elastin in Igf12/2 E18.5 lungs
(Fig. 2G–H). Additionally, we noticed a reduction in the
perivascular and parabronchial smooth muscle mass in Igf1-null
lungs, as was demonstrated with immuno-staining of actin (Fig. 2I–
J). This was not an unexpected result because IGF1 has been
broadly described to induce smooth muscle proliferation, differ-
entiation and survival [28]. To visualize lung vascular abnormal-
ities, an FITC-labeled dextran polymer solution was inoculated
into the blood stream of E18.5 embryos to visualize the lung
vascular network. Angiograms, obtained by projections of confocal
images captured from whole mounted lungs, denoted a disorga-
nized distribution and thicker blood vessels in the distal alveolar
septa of Igf12/2 lungs (Fig. 3A–B). Cross-sections of these FITC-
dextran perfused lungs showed that blood vessels in distal
parenchymal septa of Igf12/2 fetuses had thick lumens and that
they were scattered in the abundant mesenchyme, away from the
saccular space, whereas in normal control lungs, vessels had thin
diameters and were located at the periphery of septa, surrounding
saccular cavities (Fig. 3C–D and Fig. S1C–D). Morphometric
measurements of FITC-labeled blood vessel areas revealed that
section surface means were indeed significantly increased in
Igf12/2 mutant lungs (Fig. 3E). These results further support the
hypothesis that the lack of IGF1 alters vascularization and
capillary remodeling during saccular septum maturation. Collec-
tively, all the immuno-histological data suggest a role for IGF1 as a
regulator of different aspects of prenatal lung organogenesis in
mice, including saccular septum differentiation, ECM deposition,
smooth muscle production and capillary remodeling.
Differentially-expressed genes in E18.5 Igf12/2 mouse
lungs
In order to identify genes potentially involved in IGF1 function
during lung development, we analyzed global RNA gene
expression profiles of Igf12/2 vs. Igf1+/+ in E18.5 lungs. RNA
extracted from lungs with both genotypes (three independent
biological replicates per genotype, n= 3) was hybridized with
commercial high-density oligonucleotide microarrays. After bioin-
formatics analysis, statistically significant changes in gene expres-
sion occurring in lungs of both genotypes were found (data
submitted to Gene Expression Omnibus, accession number
GSE17157), and two groups of gene probe-sets were defined by
setting two different levels of false discovery rate (FDR) stringency.
Establishing an FDR,0.20 we identified 566 genes, given by 640
probe-sets, with differential expression in Igf12/2 lungs with
respect to controls. In this extended list, 200 genes were found to
be up-regulated (35%) and 366 were down-regulated (65%), with a
fold change in expression levels greater than 2.2 (Fig. S2A and
Table S1). These results indicate that IGF1 acts as a regulator of
lung gene expression. Functional annotations of these 566 genes
from different databases were used to perform high-throughput
bioinformatics analyses using software tools. Five significant
biological functions based on GO (Gene Ontology) annotations were
found using the FatyGO+ application (Fig. 4A). Genes with vascular
development, organ morphogenesis and cell growth annotations
were mostly down-regulated. Strikingly, the group of genes with
the highest gene representation corresponded to immune, defense
and inflammatory response functions, most of them up-regulated.
An additional group of genes with neural development annotations
changed their expression to up or down in similar proportions.
Genes included in each of these categories are listed in Table S2.
An analysis with the GeneCodis application, based on KEGG (Kyoto
Encyclopedia of Genes and Genomics) annotations, revealed eleven
relevant molecular pathways in which IGF1-dependent genes
could be participating (Fig. 4B). MAPK pathway-related genes
included more than 10% of the genes assigned to significantly
affected pathways. Less represented were the Wnt pathway- and
calcium pathway-related genes. More than 20% of these genes
were included in pathways involved in cell-cell or cell-ECM
adhesion; namely, focal adhesion, cell adhesion, ECM-receptor
interactions, and tight junctions. Finally, genes related to antigen
processing and presentation, leukocyte trans-endothelial migration
and the B-cell receptor, again pathways related to immune
response and inflammation functions, were also found to be
significantly represented, mostly up-regulated. The genes belong-
ing to each of these conditions are listed in Table S3. We further
analyzed genes with an FDR,0.20 using the Ingenuity Pathways
program, obtaining a unique, fused network of 68 genes organized
according to their sub-cellular localization, whose main nodes
correspond to genes with previously described regulatory functions
(Fig. S3). As expected, IGF1 appeared as a node in the extracellular
space that is repressed. Additional nodes include: VEGF, Ctgf and
Mmp2 in the extracellular space, Fn1 in the plasma membrane,
Hspa8 in the cytoplasm, and Jun, JunD, Fos, Fosb, Egr1 and Nr4a
transcription factors associated with nuclear functions.
When using a more stringent FDR cut-off (FDR,0.10), 59
genes (62 probe-sets) were identified as highly relevant IGF1 target
genes during late lung development, all of them with a fold-change
higher than 2.5 in mutant lungs as compared to controls (Fig. S2B
and Table S1). A list of these genes, first organized with respect to
their degree of over-expression and repression, and then subdi-
vided into functional categories, according to GO annotations and
published reports, is shown in Table S4. Of these 59 genes, 19 were
up-regulated and 40 were down-regulated in Igf12/2 lungs. Three
of the 59 genes (Cyr61, Jun/AP1 and Klf6) were represented by
more than one independent probe-set detected as significant in the
differential expression analyses (marked with an asterisk in Table
S4). Interestingly, some of the loci were reported to be specifically
involved in lung organogenesis (Nfib, up-regulated; and Klf2, Fgf18
and Aqp5, down-regulated) [29–32], whereas others played a more
general function in tissue development (Wnt7a and Klf6, repressed)
[17,33], were related to vasculogenesis (Cyr61, Ctgf, Vegfa, and
Xlkd1, repressed) [34–37] or to cell adhesion and ECM deposition
(Plat, Dpt, Chi3l1, Itgb6 and Msln, repressed) [38,39]. Changes in
mRNA expression of these groups of genes in Igf12/2 lungs
further support involvement of IGF1 in controlling pulmonary
organogenesis. Other groups of differentially expressed genes with
an FDR,0.10 were linked to different specific cellular functions
and/or sub-cellular compartments such as protein biosynthesis
and ribosome components (Gas5, Rpl30, Rps9, Rps10 and Rpl12,
up-regulated) [40,41], integral to the ER membrane (Pcsk6, and
IGF1 Role in Prenatal Lung Development
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83028
Upk3a, up-regulated) [42], mitochondrial enzymes (Cox7c and Bdh,
up-regulated) [43], calcium metabolism (S100a14 and Dscr,
repressed) [44], anti-proliferative and tumor suppressors (Scgb3a1
and Btg2, repressed) [45,46], chaperoning, stress response and
MAPK signaling (Hspa8, Nsep1 and Map2k7, up-regulated; Fos,
Nr4a1, Jun, Dusp1 and Egr1, down-regulated) [47–52], and other
Figure 2. Altered extracellular matrix deposition and reduced smooth muscle actin expression in IGF1-deficient embryonic lungs.
(A–D) Immuno-fluorescence analysis for laminin expression (green) in E18.5 embryos (A–B) (n = 4 per genotype), and E12.5 embryonic lungs cultured
96 h ex vivo counterstained with DAPI (blue) (C–D) (n = 3 per genotype). Cross sections of Igf1+/+ lungs (+/+) show strong staining, with a regular and
continuous distribution of laminin in basal membranes (A, C). In contrast, the Igf12/2 lungs (2/2) show a weaker (asterisks) or discontinuous (arrow)
staining in basal membranes (B, D). (E–F) Collagen staining with Sirius red of E18.5 lungs. In controls (E) collagen deposition shows a well-defined and
continuous fibrous reticular distribution in distal septa (arrows), while in the Igf12/2 lungs the stain is diffuse (asterisk) (F) (n = 3 per genotype). (G–H)
Staining of elastin fibers with orcein in blood vessels of E18.5 lungs is reduced in both intensity and thickness in blood vessel walls of Igf12/2 lungs
(H) (n = 4), as compared to controls (G) (n = 3) (arrows). (I–J) Immuno-fluorescence staining for muscle actin (monoclonal antibody clone HHF35) (red)
in bronchiolar cross-sections of E18.5 lungs counterstained with Sytox (green). Thickness of bronchiolar smooth muscle is reduced in Igf12/2 lungs (J)
compared to controls (I) (arrows). All images are representative of samples analyzed from independent experiments (n = 3 per genotype). as, airway
space; br, bronchiole; bv, blood vessel; m, mesenchyme; s, septum. Scale bar in J corresponds to 10 mm in A–B, 50 mm in C–D and G–H, and 20 mm in
E–F and I–J.
doi:10.1371/journal.pone.0083028.g002
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metabolic enzymes (Pnpo, Fech and Fthfd, repressed) [53]. Changes
in RNA levels of these genes in Igf12/2 fetal lungs clearly indicate
that IGF1 is a canonical growth factor for proper lung size
development. Again, several genes known to be involved in
immune/defense responses (H2-Aa, Gzma, and Slfn1, up-regulated;
Lcn2, Kitl and Zfp36, down-regulated) [54–57] drew our attention,
supporting the notion that a lack of IGF1 in the lung may result in
increased levels of immunological response genes. Finally, eleven
differentially expressed genes catalogued with other/unknown
functions, were found repressed in Igf12/2 lungs.
We validated the gene signature obtained using microarrays by
alternative experimental approaches in a different collection of
samples. First, we performed a quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) on a subset of the 59-gene
signature (set with FDR,0.10), consisting of 27 using RNAs from
a different collection of samples (n = 4 per genotype). The qRT-
Figure 3. Altered lung microvasculature in E18.5 Igf12/2 embryos. Cross-sectional microphotographs of E18.5 lungs perfused with FITC-
Dextran (green) to visualize the capillary network. (A–B) Representative three-dimensional projections of 14 consecutive 1 mm-thick confocal sections
taken from whole-mounted lungs analyzed from independent experiments. Whereas in wild-type embryos (A) the fine microvasculature is normally
distributed in the thin saccular septa (yellow arrow), in the Igf12/2 animals more vessels stain the thicker septa (yellow arrowhead) (B). (C–D)
Immuno-fluorescence counter-staining with anti-laminin antibodies (red) on distal sections of FITC-Dextran perfused lungs. In Igf1+/+ embryos, most
of the blood vessels in the saccular septa have a thin diameter and they are located next to the saccular space (arrows in C). In the Igf12/2 lungs, the
blood vessels show an increased diameter with a high proportion of them immersed in the abundant mesenchyme (arrowheads in D). Note the
fainter staining of laminin in Igf12/2 lungs. (E) Graphic representation of the quantization of blood vessel area in both genotypes, shown as means6
SD. **p,0.01 (Mann-Whitney U-test). In parentheses, number of lungs evaluated. as, saccular space; s, septum. Scale bars: 25 mm in A–B and 20 mm in
C–D.
doi:10.1371/journal.pone.0083028.g003
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PCR signals of those 27 loci, relative to the signal of ß2-microglobin/
Arbp used as an internal control, were included in Table S4. All the
changes obtained by qRT-PCR matched the results observed by
the microarrays in terms of ‘‘up-regulation’’ or ‘‘down-regulation’’
of the corresponding genes, although some discrepancies were
noted in the quantitative extent of the gene expression alterations.
In all cases differences in gene expression levels between genotypes
were statistically significant, as specified in Table S4. Expression of
three additional repressed genes with FDR between 0.10 and 0.20,
namely Fn, Icam1 and Atf3, was also verified by qRT-PCR (Table
S5). These genes were chosen based on their previously reported
role in lung development: Fn1 has been implicated in lung
branching morphogenesis [58], Icam1 expression was described in
endothelial and alveolar type I epithelial cells [32], and the
immediate-early response transcription factor, Atf3, implicated in
lung injury recover [59], also mediates p38 MAPK signaling, an
enzyme extensively involved in lung morphogenesis and differen-
tiation [60–62].
mRNA microarray data of Igf12/2 lungs revealed changes in
gene expression levels which were validated at the protein level
using immunoblotting of whole lung extracts to test for certain
regulatory proteins, especially transcription and growth factors.
We chose proteins that were either previously implicated in lung
organogenesis or identified with functions regulated by IGF1, such
as the transcription factors Nfib, Klf2, Egr1 and c-jun, and the
matricellular proteins Cyr61/CCN1/Igfbp10 and Ctgf/CCN2/
Igfbp8 [30,63–68]. We observed significantly increased protein
levels of Nfib and significantly decreased levels of Klf2, Egr1 and
Ctgf in the Igf12/2 lungs, all of which correlated to their changes
in mRNA levels. However, c-Jun and Cyr61 protein levels did not
change to match their reduced mRNA levels in the Igf12/2 lungs
(Fig. 5A–B). Nfib expression was further evaluated by immuno-
staining of Igf12/2 lung sections. Nuclear expression of Nfib,
mostly observed in subsets of mesenchymal cells and smooth
muscle cells surrounding bronchioles and arterioles of normal
lungs (Fig. 5C) as previously reported [29], displayed a similar
pattern in the highly abundant mesenchymal cells of Igf12/2 lungs
(Fig. 5D). Altogether, these data contribute to our understanding
of the molecular basis of delayed lung maturation in the context of
IGF1-deficiency, where IGF1 affects the expression of key
regulatory genes in lung organogenesis.
Expression of IGF System Genes and Activation of their
Signaling Mediators in the Igf12/2 Lungs
To determine if the lack of IGF1 alters the expression of IGF
system genes at the mRNA level, we analyzed the expression of
Igf2, Igf1r, Igf2r, Insr (splice variants A and B), Igfbp2, Igfbp4 and
Igfbp6, in a different set of Igf1+/+ and Igf12/2 E18.5 lungs (n = 4
per genotype) using qRT-PCR. With the exception of Igfbp2,
which showed a minor, but significant reduction (0.8-fold in
Igf12/2 respect to WT), none of the other genes showed significant
differences in transcript levels between genotypes (Fig. 6A). These
results concur with the expression profiling results obtained using
microarrays, where none of these genes were differentially
expressed.
To better understand the pulmonary phenotype of Igf12/2
mice, we compared IGF1R and IGF2 expression patterns in E18.5
lungs of control and Igf12/2 lungs by immuno-staining. We chose
IGF1R as the main cell autonomous mediator of IGF1 action, and
IGF2 as the alternative ligand signaling through IGF1R. To
identify their cellular localization, we performed immuno-co-
staining with specific markers for different pulmonary cell types
[17] (Fig. 6B–M). We found a ubiquitous staining for IGF1R
throughout the entire control lungs, although with important
differences in staining intensity among different cell compartments
and cell types, as it was reported [21]. The mutant lungs showed a
similar pattern, with only minor differences (Fig. 6B–K). In the
proximal lung we noticed prominent staining for IGF1R in the
entire bronchiolar epithelium (Fig. 6B–C, D–E and F–G). Among
bronchiolar epithelial cells, the higher levels of IGF1R corre-
sponded to Clara cells, which specifically express the Clara Cell
Secreted Protein (CCSP) marker (Fig. 6B–C). Strong IGF1R
staining was also found in endothelial cells of large vessels (Fig. 6D–
E), co-localized with smooth muscle actin (SMA) in areas of
perivascular and peri-bronchiolar smooth muscles (Fig. 6D–E). In
the distal lung, IGF1R staining was found scattered throughout
the entire parenchyma, co-localized with SMA-positive cells
Figure 4. Functional annotations of IGF1-transcriptionally regulated genes obtained from RNA microarray analysis of mouse lung
embryos. Analyses included differential expressed genes found in E18.5 Igf12/2 lungs with FDR,0.20. (A) Representation of the percentage of IGF1-
regulated genes involved in biological processes classified according to either their GO, or (B) KEGG annotations. Significant biological functions (A)
or molecular pathways (B) were determined using FatiGO+ and GeneCodis bioinformatics applications, respectively. Bars are color-coded in red for up-
regulated genes and in green for down-regulated genes. Genes included in each category of (A) and (B) are listed in Tables S2 and S3, respectively.
doi:10.1371/journal.pone.0083028.g004
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(Fig. 6D–E). IGF1R positive cells coincided with many Surfactant
Protein C Precursor (ProSPC)-stained cells, a marker that
identifies type 2 alveolar epithelial cells (Fig. 6F–G), but did not
co-localize in cells positively stained for Aquaporin 5 (Aqp5), a
type 1 pneumocyte marker (Fig. 6H–I). Interestingly, we found a
frequent co-staining of IGF1R with the CD31/PECAM capillary
endothelial marker in Igf1+/+ lungs (Fig. 6J), a pattern that was not
so evident in the Igf12/2 samples (Fig. 6K). IGF2 positive
immunostaining was intense in lung bronchiolar epithelium and
absent in the distal pulmonary parenchyma, with no differences
between genotypes (Fig. 6L–M).
Additionally, we compared total protein content and activation
levels by phosphorylation of different IGF1 signaling mediators by
immunoblotting of proteins obtained from lungs of both
genotypes. When we evaluated the expression of IGF1R, we did
not find differences between genotypes (Fig. 7A–B). Although
downstream molecular pathways for IGF1/IGF1R signaling
include the canonical Akt mediator, and activation of STAT3
transcription factor, both described to be involved in lung cells and
lung development [69,70], we did not find differences in their
expression or activation levels (Fig. 7A–B). An alternative
recognized IGF1/IGF1R signaling mediator is the MAPK
pathway, reported with implications in lung development
[60,71–73], and upon genes related to this pathway found to be
differentially expressed in the microarray analysis of Igf12/2 lungs
(Fig. 4B). Thus, when we analyzed total protein and phosphor-
ylation levels of ERK1/2, p38 and JNK MAP kinases in lung
extracts, we noticed an increase in total mean expression and
phosphorylation levels of both forms of ERK, but only the level on
pERK2 activation level was statistically significant (Fig. 7A–B). In
addition, we did not find changes in levels of expression or
activation in p38 or JNK (p46) MAP kinases (Fig. 7A–B).
Figure 5. Protein levels of selected regulatory genes found with differential expression in microarrays of RNA. (A) Representative
Western blots for Nfib, Klf2, Egr1 and c-Jun transcription factors as well as Ctgf and Cyr61 matricellular growth factors in E18.5 Igf1+/+ and Igf12/2
lungs. b-Tubulin was used as a loading control. (B) Graphical representation of densitometric measurements of specific band signals after total
protein loading normalization with ß-Tubulin. Igf1+/+ relative values were taken as 100%. In parentheses, number of samples determined. Increased
levels of Nfib in Igf12/2 lungs were statistically significant (**p,0.01), and decreased levels of Klf2, Egr1 and Ctgf were also found to be significant
(*p,0.05) (Mann-Whitney U-test). (C–D) Representative immuno-staining for Nfib in lung cross-sections analyzed from independent experiments.
Note high levels of Nfib nuclear expression in subsets of mesenchymal cells surrounding blood vessels (arrows) and bronchioles (arrowheads), more
evident and with a flattened morphology in Igf12/2 (n = 4) than in Igf1+/+ (n = 3) lungs. as, saccular space; br, bronchiole; bv, blood vessel; ß-Tub, ß-
Tubulin; s, septum. Scale bar: 20 mm.
doi:10.1371/journal.pone.0083028.g005
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Figure 6. Expression of IGF system genes in the E18.5 lung. (A) mRNA expression levels of Igf2, Igf1r, Igf2r, Insr (splice variants A and B), Igfbp2,
Igfbp4 and Igfbp6 analyzed by qRT-PCR in Igf1+/+ and Igf12/2 lungs (n = 4 per genotype). Gapdh was the endogenous control gene. Only Igfbp2 mRNA
levels were significantly reduced in Igf12/2 lungs (*p,0.05) (Mann-Whitney U-test), however note the slightly increased Igf2, Igf1r, Igf2r, InsrA and
InsrB and slightly reduced Igfbp4 and Igfbp6 mRNA mean levels in Igf12/2 lungs. (B–K) Immuno-staining of IGF1R (green labeling) counterstained in
red with lung cell-type specific markers. IGF1R staining was high in the bronchiolar epithelium (green arrows), but also found scattered throughout
the distal parenchyma (asterisks). No major differences were noted between genotypes. (B–C) Bronchiolar epithelium showed strong staining for
IGF1R (green arrows), with the highest levels co-localizing in CCSP+ Clara cells (yellow arrows). (D–E) IGF1R stained vascular endothelial cells (green
arrowheads) and co-localized with SMA (smooth muscle actin, clone 1A1 antigen) in peribronchiolar and perivascular smooth muscle (yellow arrows),
and in scattered cells of lung parenchyma (yellow arrowheads). (F–G) Co-stain with Pro-SPC (SPC) showed IGF1R co-localization in many type 2
pneumocytes (yellow arrows), more randomly distributed in controls (F) and with a more acinar-like organization in Igf12/2 lungs. (H–I) Type 1
epithelial cells, stained with Aqp5, did not co-stain with IGF1R (red arrows). (J–K) CD31 endothelial marker co-localized with IGF1R in some
parenchymal endothelial cells of Igf1+/+ lungs (yellow arrow in J), but not in Igf12/2 (white arrow in K). (L–M) Immuno-staining for IGF2 expression
(red labeling) was positive in bronchiolar epithelial cells of both genotypes (red arrows). EDTA antigen retrieval for IGF2 caused unspecific refringent
signal on red blood cells (orange arrowheads). All confocal images in B–M are representative of samples analyzed from independent experiments. as,
airway space; br, bronchiole; bv, blood vessel. Scale bars: 25 mm in B–C and F–G, 17 mm in D–E and L–M, 12 mm in H–I and 8 mm in J–K.
doi:10.1371/journal.pone.0083028.g006
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Altogether, these results suggest that IGF1 deficiency during
embryonic development did not have compensatory effects on IGF
system gene expression levels or their signaling pathway compo-
nents, although this deficiency did lead to an increased activity of
ERK2 MAP kinase.
IGF1 deficiency increases the presence of inflammatory
markers in prenatal lungs
To investigate whether the increase in expression of immune
and inflammatory genes might correspond to an accumulation of
inflammatory cells in mutant lungs, we analyzed the presence of
inflammatory cells in Igf12/2 lungs. Using immuno-staining for
the Ly-6G/6C antigen, a cell surface marker of granulocytes and
cells of myeloid lineage [74], we found a three-fold increase in the
number of stained cells on the mutant lungs (Fig. 8A–C).
Immunoblotting, of the T cell-specific CD3 antigen also revealed
a significant increase in CD3 protein levels in the Igf12/2 lungs,
pointing to an increased presence of T-cells (Fig. 8D–E). These
results indicate that the lack of IGF1 during embryonic
development could induce the recruitment of inflammatory cells
to the lung.
IGF1 functionally rescues saccular septum maturation in
ex vivo cultured lungs by regulating expression of Nfib,
Klf2, Cyr61 and Ctgf
The Igf12/2 lung histological and molecular alterations
described above are a consequence of cumulative changes due
to the absence of growth factor throughout embryogenesis, and
possibly counteracted by compensatory mechanisms that could
partially mask the precise role of IGF1 in prenatal pulmonary
organogenesis. To validate and demonstrate the direct action of
this growth factor on prenatal lung organogenesis, we studied the
effects of adding exogenous IGF1 to E16.5 explanted lobes of
normal and Igf12/2 lungs. These explants were cultured ex vivo in
defined medium using an experimental setup that allows E16.5
mouse lung tissue to growth at the air–liquid interface, in a similar
manner as previously described [75–77]. Explanted lungs of both
genotypes grew in culture proportionally to their original size
(Fig. 9A–B). Addition of IGF1 to the medium barely changed the
morphology of wild-type cultured lungs (Fig 9C). However, in
Igf12/2 lungs, IGF1 induced changes in morphology by increasing
the proportion of clear areas in the distal lobes (Fig. 9D).
Histological analyses of the normal explants revealed immature
Figure 7. Levels of IGF signaling mediators in prenatal Igf12/2 lungs. (A) Representative Western blots of total protein extracts for total
IGF1R, phosphor-(p)-Akt and total Akt, pSTAT3 and total STAT3, pERK1/2 and total ERK1/2, pp38 and total p38-alpha and pJNK and total JNK (p46),
using two representative samples from both normal and Igf12/2 E18.5 lungs. Activation levels were determined using phosphor-specific antibodies.
b-Tubulin was additionally used as a protein loading control (bottom panels). (B) Western blot band densitometric measurements of after total
protein loading normalization, using either ß-Tubulin or total content of each protein when evaluating phosphorylation levels with phosphor-specific
antibodies. Igf1+/+ relative values were taken as 100%. In parentheses, number of Western blots quantified per genotype. Increased levels of pERK2
with respect to total ERK2 was found to be significant (*p,0.05) (Mann-Whitney U-test). ß-Tub or b-Tub, ß-Tubulin.
doi:10.1371/journal.pone.0083028.g007
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distal clear spaces transected by thick septa that were still lined
with a high proportion of cubic epithelium (Fig. 9E and inset). As
expected, Igf12/2 explants showed reduced terminal spaces,
barely exhibited defined distal parenchymal septa and demon-
strated a poorly differentiated epithelium (Fig. 9F and inset).
Addition of IGF1 to cultured wild type-lungs led distal septa to
become narrowed and their epithelium to flatten (Fig. 9G and
inset). Strikingly, the effects of IGF1 were heavily increased in the
Igf12/2 explanted lungs, which had thinner septa (2 to 6 cells
thick), scarce mesenchyme, and a reduced presence of cubic
epithelial cells (Fig. 9H and inset). Positive staining for pro-SPC in
a high proportion of epithelial cells organized in acinar-like
structures in the non-IGF1-treated explants revealed their more
immature staging (Fig. 9I–J). Addition of IGF1 reduced the
proportion of cells stained for pro-SpC, and increased the
proportion of pro-SpC-negative cells with flatten morphology
(Fig. 9K–L). Thus, IGF1 addition to explanted lungs induced
pulmonary distal parenchymal septum maturation in vitro, an
action more obvious in Igf12/2 explants, which likely resembled
the maturation stage described in vivo in the normal lungs at the
E18.5 developmental stage (Fig. S1C) [23].
Next we checked if in vitro IGF1 action on the explanted lungs
induced changes in expression levels of the genes that we proposed
above as candidate targets of IGF1 action during lung organo-
genesis. When we analyzed Nfib, Klf2, Ctgf and Cyr61 protein
levels bound to laminin in the cultured lungs, we found that
exogenous IGF1 elicited different results depending on the gene
analyzed (Fig. 9M–N). When we cultured explants without IGF1
we only found significant increased levels of Nfib in the Igf12/2
explants respect to the Igf1+/+, although there were no differences
for Klf2, Cyr61, laminin and Ctgf (Fig. 9M–N). It is noteworthy
that this increase in Nfib reflects the results found in E18.5 native
lungs (Table S4 and Fig. 5). Addition of exogenous IGF1 to Igf1+/+
explants elicited a significant increase in the expression of Nfib,
Figure 8. Prenatal IGF1-deficiency during lung development increases the presence of pulmonary inflammatory cells. (A–B)
Representative immuno-staining for Ly-6G/6C (Gr1) from independent experiments in paraffin cross-sections of E18.5 lungs. Igf12/2 lungs (B) have
increased numbers of cells with positive staining as compared to wild type littermates (A) (red arrowheads) (n = 4 samples/genotype). (C) Graph
representing quantization of Gr1-positive cells in both genotypes, showing a three-fold increase in Igf12/2 lungs. Graphs represent means 6 SEM.
***p,0.001 (Mann-Whitney U-test). (D) Total CD3 protein levels, a marker for T-lymphocytes, analyzed by Western blot in two samples of each
genotype. (E) Representation of CD3 densitometric mean signal (6 SEM) after total protein loading normalization with ß-Tubulin. Five (Igf1+/+) and
four (Igf12/2) different samples were used. Increased levels of CD3 were significant (*p,0.05) (Mann-Whitney U-test). as, saccular space; s, septum;
ß-Tub, ß-Tubulin. Scale bar: 20 mm in A–B.
doi:10.1371/journal.pone.0083028.g008
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Figure 9. IGF1 induces alveolar morphogenesis and expression of target genes in prenatal lungs cultured ex vivo. E16.5 Igf1+/+ and
Igf12/2 lung lobes were cultured in defined medium for 96 h in the presence or absence of recombinant IGF1 (100 ng/mL). (A–D) Images of cultured
lobes showing the effect on explant morphogenesis induced by addition of IGF1. Note the differences in morphology shown by Igf12/2 explants
treated with IGF1 (D) (n = 10 per condition). Purple dashed lines indicate sectioning planes in E to L. (E–H) H&E staining on sections of the cultured
lungs (n = 4 per condition). Untreated explants show compact tissue with undefined septa and reduced spaces mainly lined by cuboidal epithelium
(arrows in E–F). IGF1 treatment opens tissue spaces, narrows septa and flattens the epithelium (arrows in G–H), with a more pronounced effect on
Igf12/2 explants (H). Insets in E–H are high magnifications of lung epithelium (arrows), demonstrating that it becomes thinner and flatter in both
genotypes of IGF1-treated cultures. (I–L) Immuno-histochemical staining for Pro-SPC on lung explants. The high proportion of cubic positive cells
lining the reduced aerial spaces in non IGF1-treated explants (asterisks in I–J), decrease in proportion in the epithelium of IGF1-treated tissues
(arrowheads in K–L) (n = 2 per condition). All images in A–L are representative of samples analyzed from independent experiments. (M) Immunoblots
for IGF1 target gene expressions in explanted lungs. (N) Densitometric representation of gene expression levels after total protein loading
normalization with ß-Tubulin (ß-Tub). In parentheses, quantified Western blots. IGF1 addition to explants increased levels of Nfib and laminin in lungs
of both genotypes, Ctgf in Igf1+/+explants, and Klf2 and Cyr61 in Igf12/2 samples, but it reduced levels of IGF1R in both genotypes. (*p,0.05;
**p,0.01) (Mann-Whitney U-test). as, air space; s, septum. Scale bar corresponds to 500 mm in A–D; 50 mm in E–H, and 7 mm in their insets; 20 mm in
I–L.
doi:10.1371/journal.pone.0083028.g009
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laminin and Ctgf, but did not change levels in Klf2 and Cyr61. In
contrast, in Igf12/2 cultured lungs all proteins, with the exception
of Ctgf, had significantly increased levels after addition of IGF1
(Fig. 9M–N). When we looked for Nfib immuno-localization in the
cultured lungs, we noticed that in the IGF1-untreated explants the
Nfib-positive cells were randomly distributed in the tissue,
preferentially in the mesenchymal compartment (Fig. S4A–B).
Interestingly, in the IGF1-treated tissues, cells with a stronger
signal for Nfib mainly aligned under the epithelium, a pattern
better noticed in the Igf12/2 explants (Fig. S4C–D). Independently
of whether exogenous IGF1 was added, IGF1R protein levels were
significantly higher in Igf12/2 cultured lungs than in Igf1+/+ ones.
The addition of IGF1 caused a reduction in IGF1R expression in
explants of both genotypes, probably due to feedback inhibition, as
previously reported in other biological systems (reviewed in [78]).
Taken together, these results further support the idea that IGF1
induces distal lung prenatal maturation, which acts on epithelial
and mesenchymal cells by regulating gene expression of
transcription factors Nfib and Klf2 and matricellular proteins
Cyr61 and Ctgf.
Discussion
We studied IGF1 function during embryonic pulmonary
organogenesis by analyzing the lung phenotype of the Igf12/2
mouse in a C57Bl/6J background. For this aim we compared
distinct features of Igf12/2 and Igf1+/+ prenatal lungs: i)
histopathology; ii) pulmonary transcriptome changes and their
validation at the protein level on selected regulatory genes as
possible targets of IGF1 action; iii) expression of IGF-system genes;
and iv) histopathological and molecular effects of exogenous IGF1
on ex vivo explanted lungs. This study allowed us to identify
molecular pathways and novel regulatory genes in which IGF1 is
involved during mouse lung embryonic development.
In mice, prenatal lung maturation is strain dependent, as
demonstrated by Xu et al. who compared transcriptomic
expression patterns in C57Bl/6J and A/J mice [79], and it would
explain why Igf12/2 mice have a highly variable pulmonary
phenotype in mixed genetic backgrounds [23,24]. The new
C57Bl/6J inbred background had beneficial consequences which
unified and emphasized their lung phenotype, and led us to
investigate additional aspects of IGF1 function during pulmonary
organogenesis. It is feasible that the uniform maturation delay
shown by Igf12/2 embryonic lungs in this new genetic context
contributes to increasing their mortality at birth and further
corroborates that the Igf1 mutation in mice is dependent on the
genetic background and causes higher detrimental phenotypes in
inbred backgrounds, as previously reported [11,24].
Although it is now clear that IGF1 and IGF2, signaling through
IGF1R, participate in the developmental control of fetal lungs, this
report clearly demonstrates that the role of IGF1 in lung
organogenesis is more critical than that described for IGF2. Thus,
IGF2 deficiency only afforded a subtle lung differentiation delay,
characterized by thicker and disorganized distal lung septa, which
did not compromise neonatal survival [15]. Furthermore, Igf22/2
prenatal lungs showed increased expression of IGF1, probably in
an attempt to compensate IGF2 deficiency [15]. Conversely, as
shown in this report, IGF1 pulmonary function was characterized
by a more severe lung differentiation impairment, which was not
associated with compensatory changes in the expression of IGF2.
Among the different IGF-system genes tested, we only found
decreased levels of IGFBP2 mRNA in the mutant lungs. These
data contrast with results found in Igf12/2 cochleae, where its
expression was increased [80], and emphasized the organ specific
actions of IGF1 during mouse organogenesis. It is striking that the
high levels of IGF1R observed in bronchiolar epithelium do not
entail major histological or molecular modifications related to this
cell compartment in Igf12/2 lungs. It is possible that high levels of
IGF2 revealed in the bronchiolar airway epithelium could
compensate IGF1 deficiency in the mutants and therefore
maintaining a normal IGF1R signaling and the absence of
abnormalities. However, more extended studies will be needed to
conclusively demonstrate this assumption.
Akt, STAT3 and MAP kinases, known as canonical IGF
signaling mediators, were previously implicated in controlling cell
proliferation, growth, survival and differentiation during lung
development [60,69–73]. Furthermore, prenatal mouse cochleae
of Igf12/2 embryos showed decreased activation of prosurvival
Akt and proliferation-associated ERK1/2 kinases, and increased
levels of the stress kinase p38 [80]. However, although we found a
bundle of genes related to the MAP kinase signaling pathway with
differentially expressed mRNA levels, we only found a significant
increase of ERK2 activation in Igf12/2 lungs. Since we had
previously reported elevated levels of ERK1/2 activation in highly
mitotic and undifferentiated lungs of Lif/Igf1 double knockout
mice [23], ERK2 activation seems to be a tissue specific target of
IGF1-deficiency in the lung.
E18.5 Igf12/2 lungs elicited disproportional prenatal pulmo-
nary hypoplasia, demonstrating that IGF1 plays a differential role
in organ growth, especially affecting the lung. The disproportional
lung size of prenatal E18.5 Igf12/2 lungs seems to be an outcome
of their reduced growth rates and branching morphogenesis found
during early stages of organogenesis. Thus, E12.5 Igf12/2 ex vivo
explanted lungs showed a significant reduction in size and
proliferation, in parallel to a decreased number in terminal lung
buds. Disproportionate effects on postnatal organ growth were
previously reported in Igf12/2 mice, where IGF1 deficiency
affected the growth of cochleae to a lesser extent, but had a greater
effect on the lungs, whose growth was hindered more [48,49]. The
ratio of lung to body weight was also greatly reduced in Igf1r2/2
prenatal embryos [14]. One possible reason for this reduced lung
size could be massive cell death due to the lack of IGF1/IGF1R
signaling, as was previously described in prenatal lungs of Igf1r2/2
mutant mice, and postnatal cochleae of the Igf12/2 mutants
[14,81]. However, both this study and our previous report [23],
failed to demonstrate changes in apoptotic rates of Igf12/2
prenatal lungs, and therefore suggesting that IGF1 would not play
a major role in prenatal lung survival. Concurring with these
results found in mice, there is evidence that IGF signaling also
plays roles in prenatal lung growth in humans. Thus, mutations in
IGF1 and IGF1R genes have been found in patients with general
intrauterine growth retardation [4,5], and lung hypoplasia [6].
Increased proliferation rates revealed by PCNA and BrdU
markers in E18.5 Igf12/2 lungs agree with increased RNA levels
of ribosomal proteins, known to be involved in protein biosynthesis
during mitosis [41], and with ERK2 kinase activation, reported as
parallel proliferation in early and immature stages of lung
development [23,73,82]. This increased prenatal proliferation
could be explained as an attempt to compensate for the reduced
proliferation and hypoplasia shown by Igf12/2 lungs at earlier
stages, and it may contribute to reducing airway space and lung
collapse, further resembling the findings in Igf1r2/2 embryos [14].
Moreover, since during normal prenatal pulmonary organogenesis
mitotic rates decay in favor of cell differentiation, the higher
mitotic rates found in mutant lungs could be a consequence of
their delayed differentiation. Accordingly, increased cell prolifer-
ation has also been described in lungs of different mouse mutants
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born with immature lungs, such as in T1a and Crh gene knockouts
[83,84].
Since lack of IGF1 during lung development causes a general
reduction in transcripts of target genes, and a similar result was
reported in cochleae of these mice [80], it is possible that IGF1
acts as a general transcriptomic activator during mouse organo-
genesis. Transcriptome changes found in E18.5 Igf12/2 lungs
could be considered a consequence of their developmental delay.
However, this does not seem to be the case because the changes
described herein are highly discrepant from transcriptomic profiles
reported by Xu et al. at different stages of normal perinatal mouse
lung maturation, where they describe major changes in molecular
regulators such as FoxM1, Plk1, STATS, EGFR and Notch [79],
none of which were observed in the Igf12/2 lung profile. Igf12/2
lung transcriptomic analysis revealed changes in networks of
biological functions or molecular pathways of functionally related
genes. Some of these networks were expected either in light of the
lung phenotype or due to previously described IGF1 actions, e.g.
in lung development and maturation, cell adhesion, vasculogenesis
and MAP kinase signaling. However, others could be identified as
potential novel IGF1 target pathways involved in mouse organ-
ogenesis, such as genes related to immunity/defense and Wnt
signaling pathways, although a recent publication by Ghosh et al.
suggests that IGF1 indeed promotes alveolar epithelium differen-
tiation through the activation of a non-canonical Wnt pathway
[85]. The abundance of differentially expressed genes in the
transcription and extracellular regulatory factors category further
supports a role for IGF1 as a general regulator of prenatal lung
development. However, given that the analysis in the cochlea also
rendered genes for specific cochlear maturation and cell differen-
tiation, with only three genes in common to both databases (Itgav,
Slc4a1 and Usp12) [80], this would further indicate that IGF1 acts
with a more tissue specific regulatory role during organogenesis.
E18.5 Igf12/2 lungs lacking IGF1 showed a general reduction
or alteration in ECM deposition, and conversely, addition of IGF1
to explanted lungs elicited a strong increase in laminin expression,
which corresponded to their improved epithelial maturation.
Accordingly, IGF1 was previously found to stimulate laminin,
collagen and other ECM component expressions in different cell
types [86–88] and vice versa: IGF1 expression in type II
pneumocytes was considered to be responsible for increased levels
of elastin in lungs of FGFR3/4 double mutant mice [89]. The
relevance of ECM proteins in lung organogenesis is reflected by
impaired lung alveolarization in mutant mice deficient in laminin
a5 or elastin [90,91]. ECM alterations were further supported by a
reduction in mRNA expression of genes involved in molecular
pathways that regulate cell adhesion, focal adhesion, tight
junctions, ECM-receptor interactions (e.g. Col4a4, Eln, Fn1, Itgb6,
Icam1, Plat1 and Serpine1), and the matricellular proteins Cyr61 and
Ctgf. Accordingly, the presence of collagen IV in lung basal
membranes is required for assembly of intermolecular collagen
fibers and proper embryonic lung morphogenesis [92,93]. Down-
regulation of Fn1 and integrins (e.g. Itgb6), components of focal
adhesions, indicates alterations in cell-to-cell and cell-to-ECM
interactions in the lung. Hence, Fn1 and Itgb6 deficiencies in mice
cause defects in lung branching morphogenesis and lung
emphysema, respectively, and contribute to maturation and
organization of alveolar architecture [39,58]. Finally, matricellular
proteins Cyr61 and Ctgf are themselves inducers of ECM
accumulation [66].
Our data demonstrate that the lack of IGF1 alters the
expression of multiple genes and gene pathways responsible for
differentiation of the three foremost relevant cell compartments in
the lung, namely epithelium, mesenchyme and endothelium.
Thus, we found repressed genes considered to be cell-specific
markers or regulators of epithelial maturation, such as Aqp5, Icam1,
Scgb3a1, Fgf18, Nfib, Klf2, Ctgf and Cyr61 [17,32], smooth muscle
and vascular development, e.g. actin, Actin regulator (Phactr), Eln,
Vegfa, Flt1/VegfR1, Klf2, Egr1, Ctgf and Cyr61 [29,94–97].
Consequently, IGFs signaling has previously been implicated in
lung epithelial maturation, vascularization and modulating cellular
responses in vascular smooth muscle cells and fibroblasts of
pulmonary origin [10,14,23,28,98]. Altogether, our data clearly
demonstrate that lack of IGF1 alters the expression of multiple
genes and gene pathways responsible for epithelial, mesenchymal
and endothelial lung compartments differentiation.
Our attention was also drawn to the low mRNA levels of
immediate-early response genes, such as Fos, Jun, Egr1 and Nr4a1/
Nur77 transcription factors and Cyr61 and Ctgf matricellular
proteins in Igf12/2 lungs. It is possible that these genes could
decrease their levels in an IGF1-independent direct action, e.g. as
a result of the 20 minute period of normal breathing performed by
the wild-type embryos. Accordingly, lungs from mouse mutants
with impaired breathing capabilities also show altered transcrip-
tomic levels of these immediate-early response genes [51,99].
However, the fact that IGF1 was reported to specifically induce
many of these genes in other contexts would also support the idea
that changes in expression of such genes in the lung is dependent
on IGF1 signaling [100].
Detailed analysis of Nfib and Klf2 transcription factors and Ctgf
and Cyr61 matricellular factors indicate that they are mediators of
IGF1 during lung organogenesis. Accordingly, Nfib, Klf2 and
Ctgf-deficient mice show delayed pulmonary development with
alterations in distal structures [63,68,101]. It is relevant to note
that the lung phenotype of Ctgf2/2 mice closely resembles that
observed in Igf12/2 lungs, and interestingly, they show diminished
levels of IGF1 [68]. Conversely, fetal lungs stimulated to grow by
tracheal occlusion show an increased expression of both Ctgf and
IGF1 proteins [102], data that strongly support a possible cross-
regulation of expression between both proteins during lung
development. Furthermore, Ctgf was initially categorized as a
low affinity IGFBP, named IGFBP8, due to the presence on its
sequence of an IGFBP domain [67]. In a similar context, Cyr61 is
a protein structurally related to Ctgf, that it was first named
IGFBP10 [67]. Interestingly, the expression levels of these four
genes in the highly proliferative Igf12/2 lungs correlate with their
changes in lung cancer. Thus, whereas Nfib was reported as an
oncogene in the lung due to its high expression in lung tumors,
Klf2, Cyr61 and Ctgf were considered tumor suppressor genes due
to their reduced levels [103–107]. IGF1 added to explanted lungs
induced maturation of distal lung epithelial cells as supposed,
however it did not cause the expected expression changes in all the
regulatory genes analyzed. Exact reasons for these dissimilar
results are unknown, although the fact that in vitro cultured
explants do not completely mirror the physiological, cellular and
molecular events that occur in the lungs in vivo should be
considered. Thus, the lack of blood supply, and therefore
inadequate gas and nutrient perfusion, may incite cell necrosis,
among other alterations, that could alter the normal lung cell
differentiation program and therefore confound the results.
However, in the same scenario, IGF1R expression behaves as
expected and serves as a good experimental control gene: its
expression increases in the Igf12/2 explants, probably to
compensate for the IGF1 deficit, and its expression is repressed
after addition of exogenous growth factor, a similar effect as that
described in cultured cell lines [108]. Based on our results from in
vivo and ex vivo experiments, we conclude that IGF1 induces distal
lung differentiation by differentially modulating the expression of
IGF1 Role in Prenatal Lung Development
PLOS ONE | www.plosone.org 14 December 2013 | Volume 8 | Issue 12 | e83028
Nfib, Klf2, Cyr61 and Ctgf. In order to elucidate the molecular
mechanisms underlying their expression interdependence, further
studies will be required.
To our surprise, Igf12/2 mice also showed diverse symptoms of
lung inflammation. Interestingly, Sanchez-Calderon et al. reported
a similar effect in the cochlea [80]. Since IGFs are not commonly
directly involved in these processes, we surmise that alterations in
these gene pathways could be an indirect consequence of IGF1
deficiency disrupting lung homeostasis. A feasible cause of
pulmonary inflammation could be reduction in cellular adhesion,
as it was described in other systems. Thus, the p120-catenin (a
regulator of adherent junctions) conditional mutation in skin
triggers a cascade of pro-inflammatory responses that activate
ERK1/2 signaling, which finally affects immune homeostasis
[109]. In a similar way, loss of Itgb6 in the lung causes emphysema,
mediated by TGF-ß activation and an accumulation of lympho-
cytes and neutrophils [39]. Deregulation in immune responses has
been associated with disturbances in IGF1 and IGF1R in typical
neonatal pulmonary diseases, such as respiratory distress syndrome
and bronchopulmonary dysplasia [8,9]. Interestingly, both human
diseases, which are characterized by pulmonary immaturity,
undifferentiated alveoli with the presence of hyaline membrane
and atelectasis, dilated capillaries immersed in the mesenchyme
and distorted ECM deposition [110], are correspondingly
modeled by prenatal lung phenotype of Igf12/2 prenatal mouse
mutants. A thorough understanding of the molecular mechanisms
controlling prenatal lung maturation will help to elucidate
pathogeneses of lung diseases associated with preterm birth,
providing new potential therapeutic and diagnostic tools to treat
pulmonary diseases in infants.
In conclusion, we demonstrate that IGF1 acts as a crucial
growth factor with cell-specific roles during embryonic mouse
pulmonary development, affecting proliferation during the early
stages of development, especially differentiation, adhesion and
immunity in prenatal stages. In addition, our results revealed gene
networks and novel potential regulatory target gene mediators of
IGF1 action on epithelial, mesenchymal and vascular cells in the
distal lung of prenatal mouse fetuses. Future studies aimed at
further analysis of IGF1 implication on cell signaling and gene
regulation in specific pulmonary cell types will be necessary to
better understand its function during lung organogenesis.
Materials and Methods
Ethics statement
All experiments and animal procedures were carried out in
accordance with the Guidelines laid down by the European
Communities Council Directive of 24 November 1986 (86/609/
EEC) and were revised and approved by the Bioethics Committees
of the University of Salamanca and CIBIR (Logron˜o).
Mice, embryos, histology and collagen determination
Previously generated Igf1 mutant mice [11] were backcrossed
for at least seven generations into a C57Bl/6J genetic background.
Details on mice genotyping, embryo manipulation, histological
techniques and collagen determinations are available in Methods S1
and published elsewhere [23,24]. For 5-bromo 2-deoxyuridine
(BrdU) labeling, 0.1 mg/g body mass of BrdU (Roche, Mann-
heim, Germany) was administered to pregnant females by
intraperitoneal injection. Injected animals were sacrificed 1 h
later and embryos processed for paraffin embedding.
Lung fluorescein angiograms and morphometry of blood
vessel diameter
The left ventricle of E18.5 anesthetized embryos was cannulated
and injected with 50 mL of 20 mg/mL FITC-dextran (2,000 MW)
(Sigma) in PBS. After 10 min, lungs were dissected, fixed
overnight at 4uC in 4% paraformaldehyde in PBS, washed in
PBS and either directly whole-mounted in anti-fading medium or
embedded in OCT medium (Miles Inc.), frozen in 2-methyl
butane and kept at 270uC. 10 mm cryostat sections were obtained
and mounted on glass slides for immunostaining. Whole-mounted
lungs were observed by confocal microscopy and three-dimen-
sional projections of 14 consecutive 1 mm thick images were
obtained using the LSM software package (Carl Zeiss, Oberko-
chen, Germany). The blood vessel area was quantified using
OpenLabH Software (Improvision, Coventry, UK) on sections
immunostained for laminin and counter-stained with DAPI. At
least 25 vessels from each sample on selected 406 fields located at
the distal part of the lung were measured. Statistical analyses were
performed using the Mann-Whitney U-test.
Lung organ culture
E12.5 lung explants were placed on 1 mm polycarbonate filters
(Whatmann, Go¨ttingen, Germany) over stainless-steel grids and
were cultured at the air-medium interface in IMEM defined
medium (GIBCO-Invitrogen, Paisley, UK) supplemented with
50 mg/mL apo-transferrin (Sigma) and 50 units/mg penicillin/
streptomycin [111,112]. E16.5 lung explants were cultured in the
same manner, but using DMEM/F12 defined medium (GIBCO),
supplemented with 2 mM glutamine, 100 mg/mL ascorbic acid
(Sigma), 50 units/mg penicillin/streptomycin [77,113] and, when
indicated, treated with 100 ng/mL rhIGF1 (R&D). Cultures were
maintained up to 96 h in a 5% CO2 incubator, and monitored
and photographed using an inverted microscope. Cellular
proliferation in E12.5 explants was determined by incorporation
of BrdU (Roche), following the manufacturer’s instructions by
adding 10 mM BrdU to the medium 1 h before stopping the
culture. For whole-mount BrdU staining, lung explants were fixed
in cold methanol, treated with 2 N HCl, and neutralized before
immuno-staining with a mouse monoclonal antibody to BrdU
(Roche). After incubation with a secondary antibody Cy3-anti-
mouse IgG (Jackson Immuno Research; 1:400 dilution) and
counterstaining with Sytox (250 nM; Molecular Probes) lungs
were mounted and examined by confocal microscopy. For
immuno-histochemical analyses on sections, E12.5 lung explants
were fixed and embedded in 7% gelatin (BioRad) and 15% sucrose
in PBS. E16.5 lung explants were directly embedded in OCT
medium (Miles Inc.), frozen in melting 2-methyl butane and kept
at 270uC until used. 10 mm cryostat sections were mounted on
glass slides and either analyzed with haematoxylin-eosin or
immuno-stained for BrdU.
RNA isolation, cRNA synthesis and microarray
hybridization
Total RNA from homogenized E18.5 lungs was purified using
Trizol ReagentH (Invitrogen, Carlsbad, CA) following the man-
ufacturer’s instructions, treated with 1 U/mL RNase-free DNase
(Promega), purified through RNeasy columns (Qiagen, Valencia,
CA) and quantified with RNA NanoLabH Chips (Agilent
Technologies, Palo Alto, CA). RNA was then used to synthesize
complementary RNA (cRNA) probes for hybridization to
GeneChip high-density mouse ‘whole genome’ (MOE430A2.0)
oligonucleotide microarrays from Affymetrix (Affymetrix Inc.,
Santa Clara, CA) according to protocols described in Gene
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Expression Analysis Technical Manual (http://www.affymetrix.
com). Briefly, 5 mg of total RNA obtained from three Igf1+/+ and
three Igf12/2 mouse lungs were separately reverse-transcribed into
double-stranded complementary DNA (cDNA), using the Super-
Script Choice System for DNA Synthesis (Invitrogen). cDNA was
then used as a template to synthesize cRNA by in vitro transcription
with the incorporation of biotinylated nucleotides (Enzo Diagnos-
tics, Farmingdale, NY, USA). Labeled cRNAs were fragmented
and hybridized to six Affymetrix GeneChip 430A2.0 Arrays, using
the GeneChip Fluidics Station 450 (Affymetrix). Hybridized arrays
were stained with streptavidin–phycoerythrin, according to the
manufacturer’s protocols. Finally, the stained arrays were scanned
in a GeneChip Scanner 3000 (Hewlett Packard, Palo Alto, CA,
USA). Raw data of the expression arrays were submitted to Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with
accession number GSE17157.
Bioinformatics microarray data analysis: normalization,
differential gene expression and biological classification
The RMA algorithm [114] was used for background correction
and normalization of fluorescent hybridization signals of the
microarrays as described elsewhere [115]. Bioconductor and R
were used as computational tools (www.bioconductor.org) to apply
RMA to the data set of 12 microarray hybridizations. In addition
to the six microarrays hybridized with lung-derived RNA (three
Igf1+/+ and three Igf12/2), six microarrays hybridized with
cochlear RNA (three Igf1+/+ and three Igf12/2) were included in
the analysis to normalize the hybridization signals [80]. Cochlear
RNA was obtained from the same animals or their siblings and its
purification, the synthesis of cRNA and microarray hybridization
were performed in parallel with lung RNA [80]. After quantifying
the expression level of each probe-set in all microarrays, the SAM
algorithm [116] was used to identify probe-sets displaying
significant differential expression when comparing the three
Igf12/2 lung samples to their respective three lung controls
(Igf1+/+). The method calculates the type I error or the number of
expected false positives using the calculation of the false discovery rate
(FDR parameter) [115]. In this report, two different levels of FDR
cut-off values were used: FDR=0.20 (p,0.00045; 640 probe-sets)
for high-throughput bioinformatics analysis and FDR=0.10
(p,0.00900; 63 probe-sets) to identify highly relevant IGF1 target
genes. The 640 differentially expressed probe-sets (FDR,0.20)
were functionally analyzed with three different software tools.
Biological functions were determined with the FatiGo+ application
(http://www.ncbi.nlm.nih.gov/pubmed/17478504), based on GO
gene (Gene Ontology) annotations. Over- and under-expressed genes
were compared, and those functions with p,0.1 (Fisher’s exact
test) were considered significant [117]. Molecular pathways were
analyzed with GeneCodis software (http://www.ncbi.nlm.nih.gov/
pubmed/19465387), which uses KEGG (Kyoto Encyclopedia of Genes
and Genomes) ontological terms. The list of probe-sets was compared
against the whole genome with a hypergeometric test, considering
those molecular pathways with p,0.1 as significantly relevant
[118]. Functional biological interactions were determined using
the Ingenuity Pathways AnalysisHapplication (http://analysis.
ingenuity.com/pa), a web-based software program that identifies
molecular networks by relating each gene entry to a comprehen-
sive database of known physical, transcriptional interactions
reported for <8000 mouse proteins.
Real-time Quantitative RT-PCR
Real-time quantitative (q) RT-PCR was carried out with
SYBRH Green Technology (iScriptTM One-Step RT-PCR, Bio-
Rad, Hercules, CA) as previously described [23]. Primers used are
listed in Table S6. Amplification of ß-2-microglobulin was used as an
internal control to normalize gene expression data [119], except
for the Igf-system genes in Fig. 6A, where Gapdh was instead used.
Immunohistochemistry and Western blotting
See Methods S1 for details. Primary antibodies used in
immunohistochemistry and Western blots, including their source,
dilution, reference and manufacturer, are listed in Table S7.
Supporting Information
Figure S1 Alterations in cell proliferation and histology
of distal parenchyma caused by IGF1-deficiency during
development of prenatal mouse lungs. (A–B) Immuno-
staining for PCNA in representative paraffin cross-sections shows
increased numbers of stained cells (arrows) in E18.5 Igf12/2 lungs
(2/2) in (B), when compared with wild-type littermates (+/+) in
(A). (C–D) Haematoxylin-eosin stained cross-sections of E18.5
lungs showing histological alterations in the distal parenchyma.
Normal lungs (C) show expanded saccular spaces, well-defined
thin septa (s) and red cells in capillaries (stained red) mainly lining
parenchymal septa, whereas Igf1-null lungs (D) display reduced air
spaces (asterisk) and not well-defined septa, presence of hyaline
membranes (arrowhead), and capillaries immersed in the abun-
dant mesenchyme (arrows). These results obtained from mice with
a C57Bl/6J background resemble previous data obtained from
mutant mice with an out-bred background (Moreno-Barriuso et al.
Dev Dyn 235: 2040, 2003). a, saccular space; s, septum. Scale bar in
D: 20 mm in A–B and 10 mm in C–D.
(DOC)
Figure S2 Statistical identification of differentially
expressed genes in lungs of Igf1-null E18.5 embryos.
Graphical display of statistical analysis performed to identify genes
undergoing significant changes of expression in Igf12/2 lungs
compared to normal Igf1+/+. Two different levels of false discovery
rate (FDR) stringency were used. (A) Establishing an FDR,0.20
(|D(i)|$2.136; p,0.00090), 640 probe-sets, corresponding to 566
different genes, were identified in the Igf12/2 lungs. Of those, 209
probe-sets were found up-regulated (33%) and 431 down-
regulated (67%) (See list in Table S1). (B) Considering
FDR,0.10 (|D(i)|.3.800; p,0.00045), 62 probe-sets (59 genes)
were identified as highly relevant IGF1 target genes (See
additional information in Table S4). Individual plots were
generated by significant analysis of microarrays algorithm
(SAM)-contrasting three independent microarray hybridizations,
performed with RNA obtained from lungs of three mice of each
genotype (Igf1+/+ and Igf12/2). Statistically significant gene
expression changes occurring between Igf1-null and control lungs
were identified using the SAM algorithm (Tusher et al. Proc Natl
Acad Sci U S A 98:5116, 2001). In this analysis six additional
microarrays hybridized with cochlear RNA (three Igf1+/+ and
three Igf12/2), obtained from the same mice or their littermates
and hybridized in parallel, were included for background
correction and normalization of hybridization. Differential
expression for a given gene probe-set is quantitated by D(i),
measuring the distance of the spot representing its expression value
to the no-change diagonal. Green dots identify probe-sets
presenting significant alterations of expression, depending on the
FDR limit cut-off. Black dots remaining close to the diagonal
represent probe-sets whose expression level does not show
significant change in Igf1-nulls relative to their controls.
(DOC)
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Figure S3 Network of the functional interactions among
the identified genes with differential expression using
the Ingenuity Pathways AnalysisH database and orga-
nized according to their sub-cellular localization. The
analysis included differential expressed genes found in E18.5
Igf12/2 lungs with FDR,0.20, using their functional relations
and annotations in the database. Genes in nodes are color-coded
in red (up-regulated) or green (down-regulated). The displayed
network with 68 genes was generated by fusion of two highly
significant networks consisting of 35 and 33 genes respectively, and
considering only direct relations between genes according to their
Ingenuity annotations. Note the abundance of transcription factors
networks and extracellular space proteins, among them IGF1.
(DOC)
Figure S4 Immunohystochemical staining for Nfib in
crossections of lung explants cultured ex vivo. E16.5
Igf1+/+ (A and C) and Igf12/2 (B and D) lung lobes were
explanted and cultured in defined medium for 96 h in absence (A–
B) or presence (C–D) of recombinant IGF1 (100 ng/mL). Note the
high proportion of Nfib-positive mesenchymal cells aligning under
epithelial cells of the saccular spaces in IGF1-treated samples of
both genotypes (arrows in C and D), effect that is better noticed in
Igf12/2 explants (D), and less clear in non-treated explants of both
genotypes (A and B). as, airway space; s, septum. Scale bar: 20 mm.
(DOC)
Table S1 Genes differentially expressed in microarrays
of the E18.5 Igf12/2 lungs. a List of probe sets found with
significant differential expression (FDR,0.20) in Igf12/2 lungs
and ordered according to decreasing absolute D(i) value. The first
63 probe-sets are functionally tabulated in manuscript Table S4.
b Over-expressed genes/probe-sets are shown in red and repressed
genes/probe-sets in green. c p value obtained after applying the
SAM algoritm. d R fold change relative to the logarithm scale.
Corresponds to the n value in 2n. e X, is the total fold change
calculated as antilog2 of R.
(XLS)
Table S2 Biological functions based on GO annotations,
and the assigned deregulated genes, found with signif-
icant changes with the FatyGO+ bioinformatic tool in the
differentially expressed genes of Igf12/2 lungs
(FDR,0.20) and represented in Figure 4A.
(DOC)
Table S3 Biological functions based on KEGG annota-
tions and the assigned deregulated genes, found with
significant changes by the GeneCodis bioinformatic tool
in the differentially expressed genes of Igf12/2 lungs
(FDR,0.20) and represented in Figure 4B.
(DOC)
Table S4 Genes with up-regulated and down-regulated
expression in lungs of E18.5 Igf12/2 embryos with
FDR,0.10, as listed in Table S1. a Functional assignments
given by Gene Ontology (GO in NCBI database) and as described
in the literature (see references in text). b Affimetrix probe-set
identification. One asterisk (*) marks additional probe-sets for a
given gene found with FDR,0.10. c D(i) is a parameter measuring
the statistical distance separating the calculated expression value of
each gene probe-set from the non-change diagonal plot. d R fold is
the log2 value of the fold change in overexpression (up-regulated in
Igf12/2) or repression (down-regulated in Igf12/2) of probe-sets
in the collection of microarrays. All values are highly significant
(p,0.001), as specified in Table S1and determined using the SAM
algorithm. e qRT-PCR mRNA mean fold change in Igf12/2
respect to Igf1+/+ lungs using ß2-microglobin/Arbp as internal
control for normalization (n= 4 per genotype, in different
embryonic lung RNA samples than those used in microarray
analyses). All values are highly significant between genotypes
(p,0.001; Mann-Whitney U test). * Second probe-set for a given
gene with altered expression.
(DOC)
Table S5 Data on additional selected repressed genes
found in the microarrays with FDR between 0.10 and
0.20 a which expression was corroborated by qRT-PCR.
a Additional information on microarray data for these genes is
shown in Table S1 under an FDR (False Discovery Rate) between
0.10 and 0.20. b Functional assignments given by Gene Ontology
(GO in NCBI database) and as described in the literature.
c Affimetrix probe-set identification. The asterisk (*) marks
additional gene probe-sets for a given gene (Listed in Table S1).
d D(i) is a parameter measuring the statistical distance separating
the calculated expression value of each gene probe set from the
non-change diagonal plot. e R fold is the log2 value of the fold
change measuring the repression of the probe sets in the collection
of microarrays respect to Igf12/2. All values are significant
(p,0.001 for Icam1 and Atf3; p,0.01 for Fn1), as specified in
Table S1. f qRT-PCR fold change in mRNA levels of Igf12/2
lungs respect to Igf1+/+controls, using ß2-microglobin/Arbp as
internal control for normalization (n= 4 per genotype, in different
embryonic lung RNA samples than those used in microarray
analyses). All values are significant between genotypes (p,0.01;
Mann-Whitney U test). References: [1] Sakai T, Larsen M,
Yamada KM (2003). Fibronectin requirement in branching
morphogenesis. Nature 423: 876–881. [2] Williams MC (2003).
Alveolar type I cells: molecular phenotype and development.
Annu Rev Physiol 65: 669–695. [3] Akram A, Han B, Masoom H,
Peng C, Lam E, Litvack ML, Bai X, Shan Y, Hai T, Batt J, Slutsky
AS, Zhang H, Kuebler WM, Haitsma JJ, Liu M, dos Santos CC
(2010). Activating transcription factor 3 confers protection against
ventilator-induced lung injury. Am J Respir Crit Care Med.
182:489–500.
(DOC)
Table S6 Gene Bank accession number and sequence of
primers used in qRT-PCR.
(DOC)
Table S7 Source, dilution, reference and manufacturer
of primary antibodies used in immunohistochemical
stainings and Western blots.
(DOC)
Methods S1 Mice, histology and immunodetection.
(DOC)
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